FMP374 is a dual-acting NMDA modulator aiming to overcome challenges with older NMDA antagonists. In preclinical TRD models, ...

Elevara Medicines Appoints Biotech Veteran as CEO Founder and former CEO of Nasdaq listed IO Biotech, Dr Mai-Britt Zocca ...

Cognito Therapeutics Presents Exploratory Biomarker Data at AAIC 2026 Supporting Coordinated Modulation of Lipid Transport ...

Across all study participants, 34.4% of those treated with FB102 reached FVASI50 and 12.5% attained FVASI75 at week 24.

Draig Therapeutics, a clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies, today announced the closing of an oversubscribed $65 million Series ...

Phase transformations—in which a material changes from one crystal structure to another, thereby acquiring dramatically ...

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...

Quantum materials, materials exhibiting physical behavior governed by the laws of quantum mechanics, have proved promising ...

A newly found chain-reaction phase change in 2D MoTe2 lowers energy barriers, enabling faster control of electronic and ...

Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced the initiation of the Phase III clinical trial for Rentosertib, its ...

( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled ...

Emerging wireless demands are reshaping how next-generation networks are built, from spectrum strategy to intelligent signal ...